NASDAQ:IBRX ImmunityBio Q1 2026 Earnings Report $8.64 -0.66 (-7.05%) Closing price 03:59 PM EasternExtended Trading$8.68 +0.04 (+0.46%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast ImmunityBio EPS ResultsActual EPS-$0.62Consensus EPS -$0.08Beat/MissMissed by -$0.54One Year Ago EPSN/AImmunityBio Revenue ResultsActual Revenue$44.21 millionExpected Revenue$43.07 millionBeat/MissBeat by +$1.14 millionYoY Revenue GrowthN/AImmunityBio Announcement DetailsQuarterQ1 2026Date5/7/2026TimeBefore Market OpensConference Call DateThursday, May 7, 2026Conference Call Time7:30AM ETUpcoming EarningsImmunityBio's Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) ImmunityBio Earnings HeadlinesImmunityBio (IBRX) Meeting With Turkish President Fuels Expansion Hopes, Shares Climb 10%September 22 at 8:55 PM | finance.yahoo.comDow futures slip while S&P 500, Nasdaq futures climb after AI rally: GME, IBRX, AMD, PSKY stocks in focusSeptember 21 at 12:40 AM | msn.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.September 23 at 1:00 AM | InvestorPlace (Ad)Could IBRX be a tokenized stock? Founder’s tease sends ImmunityBio traders into speculation modeSeptember 21 at 2:35 PM | msn.comBrokerages Set ImmunityBio, Inc. (NASDAQ:IBRX) Target Price at $14.20September 18, 2026 | americanbankingnews.comImmunityBio (IBRX) Moved, So What Is Drawing Fresh Attention?September 15, 2026 | finance.yahoo.comSee More ImmunityBio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ImmunityBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmunityBio and other key companies, straight to your email. Email Address About ImmunityBioImmunityBio (NASDAQ:IBRX) is a biotechnology company focused on developing and commercializing immunotherapies and other treatments designed to activate the immune system against cancer and infectious diseases. The company’s platform combines biologics, cell therapies, vaccines and other approaches intended to generate durable immune responses. Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an interleukin-15 receptor agonist designed to stimulate natural killer cells and T cells. In 2024, the U.S. Food and Drug Administration approved ANKTIVA in combination with Bacillus Calmette-Guérin for certain adults with BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors. ImmunityBio is also evaluating ANKTIVA and other investigational therapies in additional cancer settings. ImmunityBio’s development programs have included cancer vaccines, engineered cell therapies and combination regimens intended to address solid tumors and other serious diseases. The company conducts clinical development and commercial activities primarily in the United States, while its therapies have been studied through international research programs. Patrick Soon-Shiong, M.D., is the company’s founder and executive chairman and has served as its chief executive officer.View ImmunityBio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
